Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2010, Article ID 238491, 6 pages
Research Article

Effects of SR141716A on Cognitive and Depression-Related Behavior in an Animal Model of Premotor Parkinson's Disease

1Departamento de Farmacologia, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina (UFSC), Campus Universitário, Trindade, Bloco D/CCB, P.O. Box 476, 88040-970 Florianópolis, SC, Brazil
2Laboratório de Fisiologia e Farmacologia do Sistema Nervoso Central, Setor de Ciências Biológicas, Universidade Federal do Paraná (UFPR), Centro Politécnico, 81531-980 Curitiba, PR, Brazil

Received 25 March 2010; Revised 16 July 2010; Accepted 31 August 2010

Academic Editor: Alan R. Crossman

Copyright © 2010 M. T. Tadaiesky et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [14 citations]

The following is the list of published articles that have cited the current article.

  • Peter J. McLaughlin, “Reports of the death of CB1 antagonists have been greatly exaggerated: Recent preclinical findings predict improved safety in the treatment of obesity,” Behavioural Pharmacology, vol. 23, no. 5-6, pp. 537–550, 2012. View at Publisher · View at Google Scholar
  • Douglas L. Boggs, Deanna L. Kelly, Robert P. McMahon, James M. Gold, David A. Gorelick, Jared Linthicum, Robert R. Conley, Fang Liu, James Waltz, Marilyn A. Huestis, and Robert W. Buchanan, “Rimonabant for neurocognition in schizophrenia: A 16-week double blind randomized placebo controlled trial,” Schizophrenia Research, vol. 134, no. 2-3, pp. 207–210, 2012. View at Publisher · View at Google Scholar
  • Ana L. Gutiérrez-Valdez, Ricardo García-Ruiz, Verónica Anaya-Martínez, Carmen Torres-Esquivel, Jesús Espinosa-Villanueva, Leonardo Reynoso-Erazo, Rocio Tron-Alvarez, Patricia Aley-Medina, Javier Sánchez-Betancourt, Enrique Montiel-Flores, and María R. Avila-Costa, “The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson’s disease and L-DOPA-induced dyskinesia,” Behavioural Pharmacology, vol. 24, no. 8, pp. 640–652, 2013. View at Publisher · View at Google Scholar
  • Adam Michael Stewart, Michael Gebhardt, Christopher Collins, Samuel Landsman, Kyle Robinson, Allan V. Kalueff, and Evan Kyzar, “Behavioral effects of bidirectional modulators of brain monoamines reserpine and d-amphetamine in zebrafish,” Brain Research, vol. 1527, pp. 108–116, 2013. View at Publisher · View at Google Scholar
  • Michelle S. Antunes, Andre T. R. Goes, Silvana P. Boeira, Marina Prigol, and Cristiano R. Jesse, “Protective effect of hesperidin in a model of Parkinson's disease induced by 6-hydroxydopamine in aged mice,” Nutrition, vol. 30, no. 11-12, pp. 1415–1422, 2014. View at Publisher · View at Google Scholar
  • Latha Velayudhan, Mangesh Marudkar, Oliver Hands, Richard Prettyman, Jonathan Murray, Sarah Baillon, Erik van Diepen, Srinivas Suribhatla, and Sagnik Bhattacharyya, “Therapeutic potential of cannabinoids in neurodegenerative disorders: A selective review,” Current Pharmaceutical Design, vol. 20, no. 13, pp. 2218–2230, 2014. View at Publisher · View at Google Scholar
  • Xin Du, and Terence Y. Pang, “Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases?,” Frontiers in Psychiatry, vol. 6, 2015. View at Publisher · View at Google Scholar
  • Thiago Pereira da Silva, Anicleto Poli, Daniela Balz Hara, and Reinaldo Naoto Takahashi, “Time course study of microglial and behavioral alterations induced by 6-hydroxydopamine in rats,” Neuroscience Letters, vol. 622, pp. 83–87, 2016. View at Publisher · View at Google Scholar
  • Madhu Shivakumar, Vikram Joshi, Shivakumar Subbanna, and Balapal S. Basavarajappa, “Endocannabinoid system in neurodegenerative disorders,” Journal of Neurochemistry, vol. 142, no. 5, pp. 624–648, 2017. View at Publisher · View at Google Scholar
  • John C. Ashton, Megan J. Dowie, and Michelle Glass, “The Endocannabinoid System and Human Brain Functions,” The Endocannabinoid System, pp. 115–186, 2017. View at Publisher · View at Google Scholar
  • Josiel M. Mack, Anicleto Poli, Richard L. Doty, Alcir L. Dafre, Tainara M. Moura, Tuane B. Sampaio, Roger Walz, Carla I. Tasca, Rui D. Prediger, Débora Lanznaster, Franciane Bobinski, Caio M. Massari, Ariana E. Schmitz, and Luiz F. Souza, “Intranasal administration of sodium dimethyldithiocarbamate induces motor deficits and dopaminergic dysfunction in mice,” NeuroToxicology, vol. 66, pp. 107–120, 2018. View at Publisher · View at Google Scholar
  • Lívia H. Morais, Daniela B. Hara, Maíra A. Bicca, Anicleto Poli, and Reinaldo N. Takahashi, “Early signs of colonic inflammation, intestinal dysfunction, and olfactory impairments in the rotenone-induced mouse model of Parkinson’s disease,” Behavioural Pharmacology, vol. 29, pp. 199–210, 2018. View at Publisher · View at Google Scholar
  • Fanny Faivre, Anil Joshi, Erwan Bezard, and Michel Barrot, “The hidden side of Parkinson’s disease: studying pain, anxiety and depression in animal models,” Neuroscience & Biobehavioral Reviews, 2018. View at Publisher · View at Google Scholar
  • Yijuan Du, and Steven M. Graves, “Spiny Projection Neuron Dynamics in Toxin and Transgenic Models of Parkinson’s Disease,” Frontiers in Neural Circuits, vol. 13, 2019. View at Publisher · View at Google Scholar